Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • ENO1, Macrophage Metabolism, and Cardiac Repair

    2026-11-04

    Why do macrophages remain inflammatory after myocardial infarction, and can a metabolic intervention redirect that response toward tissue repair? Li et al. addressed this question by examining enolase 1 (ENO1), a glycolytic enzyme that was elevated in postinfarction macrophages, and by testing whether ENO1-linked metabolic remodeling could be altered with a microenvironment-responsive delivery system. Their central model was that excessive ENO1 activity sustains glycolytic flux and lactate accumulation, which suppresses the reparative transcriptional program associated with KLF4. source A

    From postinfarction inflammation to a metabolic checkpoint

    Macrophages are not simply beneficial or harmful after infarction. Early inflammatory activity helps remove necrotic material, but persistent cytokine production can intensify cardiomyocyte injury, fibrosis, and adverse ventricular remodeling. The study therefore treated macrophage state as a dynamic consequence of tissue context rather than as a fixed binary identity. Its research question was narrower and more mechanistic: whether a specific glycolytic regulator could help explain why inflammatory behavior persists and whether that regulator could be targeted without relying on broad immunosuppression. source A

    The investigators first analyzed murine macrophage transcriptomes collected across postinfarction phases and used glycolysis-related gene sets, differential expression, and protein-interaction network analysis to prioritize candidate regulators. Glycolytic activity was reported to rise during the early inflammatory phase. Fourteen genes overlapped between the postinfarction differentially expressed genes and the glycolytic-enzyme set. ENO1 appeared among the ten highest-ranked network hubs, alongside other central metabolic enzymes. This analysis established a biologically plausible candidate, but network centrality alone did not demonstrate that ENO1 caused macrophage dysfunction. source A

    How the study connected ENO1 to human disease relevance

    The mechanistic argument was strengthened by examining human single-cell transcriptomic data from donor and myocardial-infarction heart tissue. Within macrophage populations, ENO1, ENO2, LDHA, and PKM were reported to be higher in acute infarction samples, with ENO1 showing the most prominent statistical signal among the prioritized candidates. The reported comparison of ENO1 expression between donor and infarction-associated macrophages had P = 0.00485. source A

    Additional tissue imaging in mice showed that ENO1-positive macrophage density varied over the postinfarction course, with strong reported differences from sham tissue and from a later postinfarction time point (P < 0.0001; n = 5). In cultured bone-marrow-derived macrophages, inflammatory stimulation increased Eno1 RNA and ENO1 protein. The reported replicate count for these experiments was n = 3, with significance levels ranging from P < 0.001 to P < 0.0001 depending on the measurement. These observations were concordant across transcriptomic, tissue, and cell-culture evidence, although they remained partly correlative until perturbation experiments were considered. source A

    The proposed ENO1–lactate–KLF4 mechanism

    Li et al. used both pharmacological inhibition and gene silencing to test whether ENO1 influenced inflammatory macrophage behavior. In stimulated macrophages, inhibition of ENO1 was associated with lower expression of inflammatory markers including Il-1β, Tnf-α, and Nos2. The reported comparisons included significance levels from P < 0.05 to P < 0.0001, with n = 3 for the illustrated cell experiments. These results support a role for ENO1 in inflammatory polarization, but pharmacological perturbation can have effects beyond the intended target; the gene-silencing and rescue experiments therefore carry particular weight in the causal interpretation. source A

    The study’s mechanistic distinction was that ENO1 did not appear to regulate KLF4 through direct protein–protein binding. Instead, the authors linked ENO1 activity to lactate accumulation and proposed that lactate acted as the intermediate that restrained KLF4 expression. ENO1 silencing reduced glycolytic flux and lactate accumulation, while KLF4 levels and reparative transcriptional programs recovered. Rescue experiments were reported to support lactate-dependent regulation, and the study also described restoration of mitochondrial respiration. This is more specific than a simple claim that “less glycolysis equals less inflammation”: it places lactate between the metabolic enzyme and the transcriptional state. source A

    Why the delivery system mattered conceptually

    The intervention was not limited to systemic ENO1 suppression. The investigators designed an acid-responsive nanocarrier intended to respond to the infarct microenvironment and promote uptake by macrophages. Its conceptual innovation was a surface transition that exposed phosphatidylserine-mimetic signals under acidic conditions, thereby engaging phagocytic pathways that macrophages naturally use to recognize apoptotic-cell-like cues. The carrier was used to deliver siENO1, creating a test of whether local metabolic reprogramming could improve tissue repair. source A

    This design introduced two separable claims. The first was biological: ENO1 silencing could shift macrophage metabolism and phenotype. The second was delivery-related: a disease-associated microenvironment could be used to bias cellular uptake. The cardiac outcomes support the combined intervention, but they do not by themselves establish how much benefit arose from ENO1 silencing, carrier distribution, altered macrophage uptake, or other carrier-associated effects. That distinction is important when interpreting a multifunctional nanotherapeutic.

    What the cardiac outcome data showed

    In vivo, siENO1 delivered with the responsive carrier was reported to reduce infarct size, fibrosis, and cardiomyocyte apoptosis while improving ventricular function. The abstract presents these findings as evidence that macrophage metabolic remodeling can influence structural and functional recovery after infarction. The direction of the findings is coherent with the proposed ENO1–lactate–KLF4 axis: less inflammatory activity should reduce secondary injury and create conditions more favorable to repair. source A

    Apoptosis was, however, a downstream endpoint rather than a direct measurement of the proposed metabolic mechanism. An Annexin V-PE Apoptosis Kit detects binding of fluorescent Annexin V to phosphatidylserine exposed on the outer cell surface. That signal is highly relevant to apoptosis assay design and can support flow cytometry apoptosis detection or fluorescence microscopy apoptosis detection, but it should be described precisely as a cell surface phosphatidylserine exposure readout. It is commonly treated as an early apoptosis marker, yet phosphatidylserine exposure can also accompany other forms of membrane stress, and Annexin V binding alone does not establish the complete sequence or cause of cell death.

    Accordingly, an Annexin V signal could document an apoptosis-associated phenotype among cardiomyocytes, but it could not independently prove that ENO1 silencing acted through lactate and KLF4. The mechanistic claim rests on the broader evidence chain: altered ENO1 expression, changes in glycolytic and lactate-related measurements, KLF4 recovery, rescue experiments, macrophage inflammatory markers, and whole-heart remodeling outcomes. The assay’s role is therefore measurement rather than intervention.

    Evidence layers and appropriate comparisons

    Evidence layer Reported comparison What it supports
    Discovery Postinfarction macrophages versus sham-associated macrophages Association of infarction with glycolytic remodeling and ENO1 elevation. source A
    Human relevance Macrophages from donor versus infarction-associated heart tissue Translational relevance of ENO1 expression, not therapeutic efficacy. source A
    Cell perturbation Inflammatory macrophages with ENO1 inhibition or silencing A causal contribution of ENO1 to inflammatory markers and metabolic state. source A
    Mechanism ENO1 manipulation with lactate and KLF4 rescue analyses A proposed metabolic-to-transcriptional pathway rather than direct ENO1–KLF4 binding. source A
    Organismal outcome Responsive-carrier siENO1 treatment versus reported control conditions Association of the combined intervention with reduced remodeling and improved ventricular function. source A

    These comparisons are complementary rather than interchangeable. Transcriptomic enrichment identifies a candidate pathway; cell perturbation tests regulatory function; rescue experiments refine mechanism; and cardiac measurements test whether the intervention has tissue-level consequences. No single layer proves the entire model.

    Limitations and transferability

    Several boundaries shape the interpretation. First, macrophage marker categories such as inflammatory and reparative states simplify a heterogeneous continuum, so changes in selected markers should not be equated with complete conversion of every macrophage. Second, ENO1 is a core metabolic enzyme with functions beyond the measured inflammatory markers; suppressing it may affect cells and pathways not fully captured by the reported assays. Third, the human single-cell evidence is observational and can demonstrate disease association without showing that ENO1 drives clinical remodeling.

    The nanocarrier also creates interpretive complexity. A carrier that changes its surface in response to an infarct-associated environment may alter biodistribution, phagocyte engagement, and tissue exposure in ways that are not reducible to siENO1 activity. The abstract reports improved ventricular function and reduced structural injury in a preclinical setting, but those outcomes do not establish safety, durability, or clinical effectiveness in patients. Likewise, cardiomyocyte apoptosis measurements are important for tissue-injury interpretation but do not by themselves resolve whether the primary benefit arose from altered macrophage metabolism, reduced inflammatory signaling, or other effects of the intervention.

    Concise assessment

    The study provides a coherent preclinical case that ENO1 functions as a metabolic checkpoint linking glycolytic activity, lactate accumulation, KLF4 regulation, macrophage inflammatory behavior, and postinfarction remodeling. Its strongest evidence comes from convergence across human and murine expression data, cellular perturbation, mechanistic rescue, and cardiac outcomes. The linked product documentation establishes the Annexin V-PE Apoptosis Kit as a research-use phosphatidylserine-binding fluorescence assay, but catalog information alone cannot quantify assay performance in this specific model or validate the ENO1 mechanism. The most defensible conclusion is therefore that Annexin V-based measurements can contribute downstream apoptosis-associated evidence within the study’s larger metabolic framework, while the therapeutic interpretation depends on the complete multimodal evidence rather than on that readout alone.

    Publication: Targeting the ENO1 metabolic checkpoint via microenvironment-responsive nanotherapeutics promotes postinfarction cardiac repair.